Preview of new drugs for overactive bladder and incontinence: Darifenacin, solifenacin, trospium, and duloxetine

Current Urology Reports

Volumn 5, Issue 5, 2004, Pages 359-367

  Kershen, Richard T ^a   Hsieh, Mike ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Detrusor Overactivity; Duloxetine; Overactive Bladder; Oxybutynin; Stress Urinary Incontinence

Indexed keywords

BENZOFURAN DERIVATIVE; DARIFENACIN; DULOXETINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NORTROPANE DERIVATIVE; PYRROLIDINE DERIVATIVE; QUINUCLIDIN 3' YL 1 PHENYL 1,2,3,4 TETRAHYDROISOQUINOLINE 2 CARBOXYLATE MONOSUCCINATE; QUINUCLIDIN-3'-YL-1-PHENYL-1,2,3,4-TETRAHYDROISOQUINOLINE-2-CARBOXYLATE MONOSUCCINATE; QUINUCLIDINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; TETRAHYDROISOQUINOLINE DERIVATIVE; THIOPHENE DERIVATIVE; TROSPIUM CHLORIDE;

CLINICAL TRIAL; HUMAN; REVIEW; URINE INCONTINENCE;

BENZOFURANS; CLINICAL TRIALS; HUMANS; MUSCARINIC ANTAGONISTS; NORTROPANES; PYRROLIDINES; QUINUCLIDINES; SEROTONIN UPTAKE INHIBITORS; TETRAHYDROISOQUINOLINES; THIOPHENES; URINARY INCONTINENCE;

EID: 16644394660     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-004-0083-x     Document Type: Article

References (64)

1. Rovner ES, Wein AJ: Incidence and prevalence of overactive bladder. Curr Urol Rep 2002, 3:434–438. DOI: 10.1007/s11934-002-0093-5
2. Luber KM: The definition, prevalence, and risk factors for stress urinary incontinence. Rev Urol 2004, 6(suppl 3):S3-S9.
3. Abrams P, Cardozo L, Fall M, et al.: The standardization of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn 2002, 21:167–178. DOI: 10.1002/nau.10052
4. Igawa Y: Discussion: functional role of M1,M2, and M3 muscarinic receptors in overactive bladder. Urology 2000, 55(suppl_5A):47–49. DOI: 10.1016/S0090-4295(99)00493-8
5. Napier C, Gupta P: Darifenacin Is Selective for the Human Recombinant M3 Receptor Subtype. Heidelberg, Germany: ICS; 2002. http://contnet.org|url. Accessed May 4, 2004.
6. Miyamae K, Masaki Y, Murakami S, et al.: Pharmacological effects of darifenacin on human isolated urinary bladder. Pharmacology 2003, 69:205–211 DOI: 10.1159/000073665
7. Chapple CR, Yamanishi T, Chess-Williams R: Muscarinic receptor subtypes and management of the overactive bladder. Urology 2002, 60:82–88. DOI: 10.1016/S0090-4295(02)01803-4
8. Stevens L, Chess-Williams R, Chapple CR: Muscarinic receptor function in the idiopathic overactive bladder. J Urol 2004, 171(suppl 4):527a.
9. Eglen RM: Muscarinic receptors and gastrointestinal tract smooth muscle function. Life Sci 2001, 68:2573–2578. DOI: 10.1016/S0024-3205(01)01054-2
10. Watson GE, Culp DJ: Muscarinic cholinergic receptor subtypes in rat sublingual glands. Am J Physiol 1994, 266:C335-C342.
11. Newgreen DT, Anderson DW, Carter AJ, et al.: Darifenacin: a novel bladder-selective agent for the treatment of urge incontinence. Neurourol Urodyn 1995, 14:555–557.
12. Moriya H, Takagi Y, Nakanishi T, et al.: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci 1999, 64:2351–2358. DOI: 10.1016/S0024-3205(99)00188-5
13. Hedge SS, Choppin A, Bonhaus D, et al.: Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol 1997, 120:1409–1418. DOI: 10.1038/sj.bjp.0701048
14. Scarpero HM, Dmochowski RR: Muscarinic receptors: what we know. Curr Urol Rep 2003, 4:421–428. DOI: 10.1007/s11934-003-0021-3
15. Braverman AS, Ruggieri MR, Pontari MA: The M2 muscarinic receptor subtype mediates cholinergic bladder contractions in patients with neurogenic bladder dysfunction. J Urol 2001, 165:36.
16. Tong YC, Chin WT, Cheng JT: Alterations in urinary bladder M2- muscarinic receptor protein and mRNA in 2-week streptozotocin-induced diabetic rats. Neurosci Lett 1997, 277:173–176. DOI: 10.1016/S0304-3940(99)00871-X
17. Pontari MA, Braverman AS, Ruggieri MR: The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol 2004, 286:R874-R880.
18. Rovner ES, Wein AJ: Update on overactive bladder: pharmacologic approaches on the horizon. Curr Urol Rep 2002, 4:385–390. DOI: 10.1007/s11934-003-0013-3
19. Kerbusch T, Milligan PA, Karlsson MO: Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data. Br J Clin Pharmacol 2004, 57:170–180. DOI: 10.1046/j.1365-2125.2003.01988.x
20. Rosario DJ, Cutinha PE, Chapple CR: The effects of single-dose darafenacin on cystometric parameters and salivary flow in patients with urge incontinence secondary to detrusor instability. Eur Urol 1996, 30:240.
21. Rosario DJ, Smith DJ, Radley SC, et al.: Pharmacodynamics of anticholinergic agents measured by ambulatory urodynamic monitoring: a study of methodology. Neurourol Urodyn 1999, 18:223–233. DOI: 10.1002/(SICI)1520-6777(1999)18:3<223::AID-NAU9>3.0.CO;2-6
22. Mundy AR, Abrams P, Chapple CR, Neal DE: Darifenacin, the First Selective M3 Antagonist for Overactive Bladder: Comparison with Oxybutynin on Ambulatory Urodynamic Monitoring and Salivary Flow. Seoul, Korea: ICS; 2001. http://contnet.org. Accessed May 4, 2004.
23. Chapple CR, Rechberger T, Al-Shukri S, et al.: Randomized, double-blind, placebo- and tolterodine-controlled trial of the once-daily anti-muscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004, 93:303–310. The first phase-3 study of an antimuscarinic agent to evaluate urgency as a primary efficacy variable in patients with OAB. Patients who received solifenacin experienced statistically significant reductions in daily urgency episodes relative to placebo. DOI: 10.1111/j.1464-410X.2004.04606.x
24. Khullar V: Darafenacin, an M3 selective receptor antagonist, reduces the frequency of nocturnal awakening, an important symptom of overactive bladder [Abstract 491]. J Urol 2004, 171(suppl):131.
25. Haab F, Stewart L, Dwyer P: Darafenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004, 45:420–429. DOI: 10.1016/j.eururo.2004.01.008
26. Ikeda K, Kobyashi S, Miyata K, et al.: M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002, 366:97–103. DOI: 10.1007/s00210-002-0554-x
27. Kobayashi S, Ikeda K, Miyata K: Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci 2004, 74:843–853. DOI: 10.1016/j.lfs.2003.07.019
28. Hatanaka T, Ukai M, Ohtake A, et al.: In vitro tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats and monkeys [Abstract 312]. Presented at the International Continence Society Meeting. Florence: October 5–9, 2003.
29. Ohtake A, Hatanaka T, Ikeda K, et al.: In vivo bladder selective profile of solifenacin succinate (YM905) over salivary gland in mice and rats [Abstract 297]. Presented at the International Continence Society Meeting. Florence: October 5–9, 2003.
30. Smulders RA, van Alphen W, Visser J, et al.: Multiple dosing with YM905, a novel, bladder-selective antimuscarinic, in healthy men: safety, tolerability, and pharmacokinetics [Abstract 439]. Presented at the International Continence Society Meeting. Heidelberg, Germany: August 28–30, 2002.
31. Chapple CR, Arano P, Bosch JH, et al.: Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase-2 dose-finding study. BJU Int 2004, 93:71–77. DOI: 10.1111/j.1464-410X.2004.04561.x
32. Chapple CR: Darifenacin is well tolerated and provides significant improvement in the symptoms of overactive bladder: a pooled analysis of phase-3 studies [Abstract 487]. J Urol 2004, 171(suppl):130. Results of pooled data are presented from three large multicenter, double-blind, placebo-controlled studies assessing the efficacy, safety, and tolerability of darifenacin.
33. Gittelman M, Klimberg I, Fincer R, et al.: Two randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter studies assess the efficacy and safety of daily oral administration of 10mg YM905 versus placebo in male and female subjects with overactive bladder [Abstract DP43]. J Urol 2003, 169(suppl):349.
34. Kaufman J, Aurora CO, Knapp P: YM905 10mg increases the proportion of male and female patients with overactive bladder who become continent [Abstract DP49]. J Urol 2003, 169(suppl):351.
35. Hofner K, Oelke M, Machtens S, Grunewald V: Trospium chloride: an effective drug in the treatment of overactive bladder and detrusor hyper-reflexia. World J Urol 2001, 19:336–343. DOI: 10.1007/s003450100225
36. Pak RW, Petrou SP, Staskin DR: Trospium chloride: A quaternary amine with unique pharmacologic properties. Curr Urol Rep 2003, 4:436–440. A comprehensive review on the unique properties of trospium chloride. DOI: 10.1007/s11934-003-0023-1
37. Fusgen I, Hauri D: Trospium chloride: an effective option for medical treatment of bladder overactivity. Int J Clin Pharmacol Ther 2000, 38:223–234.
38. Sand P, Dmochowski R: Trospium chloride improves symptoms of overactive bladder within one week [Abstract 370]. Presented at the 33rd Annual Congress of the International Continence Society. Florence, Italy: October 5–9, 2003.
39. Cardozo L, Prescott K, Serdarevic D, Skillem L: Can medication prolong warning time? Presented at the 33rd Annual Congress of the International Continence Society. Florence, Italy: October 5–9, 2003. http://contnet.org
40. Alloussi S, Laval KU, Eckert R, et al.: Trospium chloride in patients with motor urge syndrome: a double-blind, randomized, multicenter, placebo-controlled study. J Clin Res 1998, 1:439–451.
41. Stohrer M, Bauer P, Giannetti BM, et al.: Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries: a multicenter, placebocontrolled, double-blind trial. Urol Int 1991, 47:138–143. DOI: 10.1159/000282207
42. Madersbacher H, Stohrer M, Richter R, et al.: Trospium chloride versus oxybutynin: a randomized, double-blind, multicenter trial in the treatment of detrusor hyper-reflexia. Br J Urol 1995, 75:452–456.
43. Halaska M, Ralph G, Wiedemann A, et al.: Controlled, doubleblind, multicenter clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003, 20:392–399.
44. Hofner K, Halaska M, Primus GL, et al.: Tolerability and efficacy of trospium chloride in a long-term treatment (52 weeks) in patients with urge syndrome: a double-blind, controlled, multicenter clinical trial. Neurourol Urodyn 2000, 19:487–488.
45. Zinner N, Gittelman M, Harris R, et al.: Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004, 171:2311–2315. DOI: 10.1097/01.ju.0000127742.73136.0c
46. Todorova A, Vonderheid-Guth B, Dimpfel W: Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001, 41:636–644. DOI: 10.1177/00912700122010528
47. Espey MJ, Downie JW, Fine A: Effect of 5-HT receptor and adrenoceptor antagonists on micturition in conscious cats. Eur J Pharmacol 1992, 221:167–170. DOI: 10.1016/0014-2999(92)90788-6
48. Gajewski J, Downie JW, Awad SA: Experimental evidence for a central nervous system site of action in the effect of alphaadrenergic blockers on the external urinary sphincter. J Urol 1984, 132:403–409.
49. Rajaofetra N, Passagia JG, Marlier L, et al.: Serotoninergic, noradrenergic, and peptidergic innervation of Onuf’s nucleus of normal and transected spinal cords of baboons (Papio). J Comp Neurol 1992, 318:1–17. DOI: 10.1002/cne.903180102
50. Thor KB, Katofiase M: Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neuronal control of lower urinary tract function in the chlorolose-anesthetized female cat. J Pharmacol Exp Ther 1995, 274:1014–1024.
51. Sharma A, Goldberg MJ, Cerimele BJ: Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000, 40:161–167. DOI: 10.1177/00912700022008810
52. Lantz RJ, Gillespie TA, Rash TJ, et al.: Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 2003, 31:1142–1150. DOI: 10.1124/dmd.31.9.1142
53. Norton PA, Zinner NR, Yalcin I, et al.: Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002, 187:40–48. The first placebo-controlled efficacy trial of duloxetine. Duloxetine resulted in statistically significant dose-dependent decreases in IEF with corresponding improvements observed in PGI-I and I-QOL scores. DOI: 10.1067/mob.2002.124840
54. Dmochowski RR, Miklos JR, Norton PA, et al.: Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003, 170:1259–1263. DOI: 10.1097/01.ju.0000080708.87092.cc
55. Van Kerrebroeck P, Abrams P, Lange R, et al.: Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG 2004, 111:249–257. DOI: 10.1111/j.1471-0528.2004.00067.x
56. Millard RJ, Moore K, Renchen R, et al.: Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int 2004, 93:311–318. DOI: 10.1111/j.1464-410X.2004.04607.x
57. Weston FL, Elser DM, Lawn O, et al.: Controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment, and no treatment in women with stress urinary incontinence [Abstract]. AUA 2004, 1239.
58. Raskin J, Goldstein DJ, Mallinckrodt CH, et al.: Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2004, 64:1237–1244. DOI: 10.4088/JCP.v64n1015
59. Schatzberg AF: Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. J Clin Psychiatry 2003, 64:30–37. DOI: 10.4088/JCP.v64n0107
60. Diokno AC, Appell RA, Sand PK, et al.: Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003, 78:687–695.
61. Appell RA, Sand P, Dmochowski R, et al.: Prospective, randomized, controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001, 76:359–363. DOI: 10.4065/76.4.358
62. Anderson RU, Mobley D, Blank B, et al.: Once daily controlled versus immediate-release oxybutynin chloride for urge urinary incontinence. J Urol 1999, 161:1809–1812. DOI: 10.1016/S0022-5347(05)68810-6
63. Van Kerrebroeck P, Kreder K, Jonas U, et al.: Tolterodine oncedaily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001, 57:414–421. DOI: 10.1016/S0090-4295(00)01113-4
64. Dmochowski RR, Davila GW, Zinner NR, et al.: Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002, 168:580–586. DOI: 10.1016/S0022-5347(05)64684-8